Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Status:
Active, not recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA
bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES
Syndrome.